SCHEMBL3963199

SCHEMBL3963199

COc1ccc(C(=O)O)c2ccsc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
TDP1 Q9NUW8 3/20 0.47
CDC25B P30305 2/20 0.45
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
ECE1 P42892 1/20 0.43
HSD17B10 Q99714 2/20 0.43
CSNK2A1 P68400 4/20 0.42
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
POLB P06746 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 1/20 0.40
NR4A1 P22736 1/20 0.40
RECQL P46063 1/20 0.40
KMT2A Q03164 1/20 0.40
ESR2 Q92731 1/20 0.40
HTT P42858 1/20 0.40
MYC P01106 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6232967 0.87 CDC25B (0.49) MAPTTDP1CDC25BKDM4EALDH1A1
SCHEMBL11659290 0.80 CYP1A2 (0.42) MAPTTDP1KDM4EALDH1A1HPGD
SCHEMBL3151189 0.78 MAPT (0.51) MAPTALDH1A1ECE1CSNK2A1MEN1
SCHEMBL5600660 0.73 CA9 (0.50) KDM4EALDH1A1ECE1CSNK2A1MAPK1
SCHEMBL4798575 0.73 MAPT (0.47) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6235702 0.73 ALDH1A1 (0.50) MAPTCDC25BKDM4EALDH1A1HPGD
SCHEMBL910845 0.72 MAPT (0.46) MAPTKDM4EALDH1A1HPGDCSNK2A1
SCHEMBL4469856 0.72 CDC25B (0.78) MAPTTDP1CDC25BKDM4EALDH1A1
SCHEMBL4796684 0.72 MAPT (0.43) MAPTALDH1A1CSNK2A1MAPK1MEN1
SCHEMBL2995013 0.71 ALDH1A1 (0.43) MAPTTDP1KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG MAPT 2245/4885TDP1 810/4885CDC25B 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.